Vunakizumab, an interleukin-17 inhibitor, shows improved efficacy over placebo in treating active psoriatic arthritis at week ...
FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and drug label updates.
Vunakizumab significantly improved clinical responses in active psoriatic arthritis in a phase 2 trial. Read more about the study.
A systematic review and meta-analysis evaluate treatment-emergent adverse events associated with trastuzumab deruxtecan in ...
Although a growing percentage of emergency department visits require immediate treatment, throughput in EDs is improving, according to Vizient’s latest “System of CARE” report, published Feb. 5. In ...
The FDA grants Fast Track designation to sonelokimab for moderate to severe palmoplantar pustulosis, a chronic inflammatory skin disease.
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results